C12N 2820/002
Inducible or controllable
Official title: inducible or controllable
C12N2820/002 (Inducible or controllable) appears on 28 US grants and 62 published applications in this corpus.
Search patents in C12N- Granted patents
- 28
- Published applications
- 62
- Assignees
- 30
- Inventors
- 103
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 4 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 3 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 1 | 2 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 4 |
| 2015 | 1 | 0 |
| 2016 | 1 | 3 |
| 2017 | 1 | 3 |
| 2018 | 1 | 0 |
| 2019 | 3 | 3 |
| 2020 | 0 | 3 |
| 2021 | 1 | 4 |
| 2022 | 1 | 6 |
| 2023 | 4 | 5 |
| 2024 | 4 | 3 |
| 2025 | 1 | 8 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Enumeration of genetically engineered microorganisms by live cell counting techniques1 Sep 2026US 12,721,882 B2Synlogic Operating Company, Inc.
- Mammalian cells comprising integrated CAS9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites4 Aug 2026US 12,698,514 B2Regeneron Pharmaceuticals, Inc.
- Large vectors and methods for high-yield production10 Mar 2026US 12,570,990 B2Katholieke Universiteit Leuven
- Single-vector Type I vectors2 Sep 2025US 12,404,513 B2SNIPR Biome ApS
- Engineered phosphoenolpyruvate carboxylase enzymes17 Dec 2024US 12,168,773 B2The Regents of the University of California
- Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites10 Sep 2026US 2026/0265784 A1Regeneron Pharmaceuticals, Inc.
- Methods for reprogramming and gene editing cells28 May 2026US 2026/0146264 A1Factor Bioscience Inc.
- Genetic switch16 Apr 2026US 2026/0103725 A1
- Hydrogel-carriers for induction of plant morphogenesis5 Mar 2026US 2026/0060193 A1Keygene N.V.
- Single-vector type i vectors22 Jan 2026US 2026/0022389 A1SNIPR Biome ApS
Most cited
By later US patents
- Vectors for tissue-specific replication124US 5,998,205 AGenetic Therapy, Inc. · 1999
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- Isolation of novel AAV's and uses thereof63US 9,596,835 B2University of Massachusetts · 2017
- Isolation of novel AAV's and uses thereof28US 10,300,146 B2University of Massachusetts · 2019
- Isolation of novel AAV's and uses thereof21US 10,166,297 B2University of Massachusetts · 2019